Gubra A/S
GUBRA | CO
Overview
Corporate Details
- ISIN(s):
- DK0062266474
- LEI:
- 254900T17RRFZONO6W53
- Country:
- Denmark
- Address:
- Hørsholm Kongevej 11 B, 2970 Hørsholm
- Website:
- https://www.gubra.dk/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of development milestone payments and potential royalties from the D&P business.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nattaro Labs AB | Sweden | NATTA | |
|
Neovacs | France | ALNEV | |
|
Newron Pharmaceuticals S.p.A. | Italy | NWRN | |
|
NextCell Pharma AB | Sweden | NXTCL | |
|
NextFerm Technologies Ltd. | Israel | NXFR | |
|
NFL Biosciences | France | ALNFL | |
|
Nortem BioGroup | Spain | MLBIO | |
|
Novo Nordisk | Denmark | NOVO | |
|
NRGene Technologies Ltd. | Israel | NRGN | |
|
NUFORMIX PLC | United Kingdom | NFX |